Clinical trial NCT05064618: Investigator-initiated Clinical Trial of MIKE-1
Official title: Phase I/II Investigator-initiated Clinical Trial of MIKE-1 With Gemcitabine and Nab-paclitaxel Combination Therapy for Unresectable Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Pancreatic Cancer
Keywords: Am80
Meflin
Cancer-associated fibroblasts
Tamibarotene
ISLR
Cancer-restraining CAFs
Cancer-promoting CAFs
MIKE-1
Vitamin A
Lead sponsor: Nagoya University
Sponsor class: OTHER
Collaborators: name: Japan Agency for Medical Research and Development
First posted: 2021-10-01
Enrollment: 55
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Groups of participants are assigned to receive interventions based on prior milestones being reached in the study, such as in some dose escalation and adaptive design studies.
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and tolerability of Am80（Generic name: Tamibarotene, Development code: MIKE-1） in combination with gemcitabine (GEM) and nab-paclitaxel (nab-PTX) in patients with unresectable pancreatic cancer and to determine the recommended dose. Efficacy will also be exploratively investigated.

Detailed description: Cancer-associated fibroblasts (CAFs) are an important component of the tumor microenvironment. The most common notion in the CAF research field has been that CAFs promote cancer progression through various mechanisms. Interestingly, however, recent studies have revealed that CAFs are heterogeneous and that CAF subsets that suppress cancer progression (cancer-restraining CAFs \[rCAFs\]) must exist in addition to well-characterized cancer-promoting CAFs (pCAFs). However, the identity and specific markers of rCAFs have not been reported.

The investigators recently identified Meflin as a specific marker protein of rCAFs in pancreatic and colon cancers. The investigator's studies revealed that rCAFs are similar to a small subset of resident fibroblasts, which is consistent with the famous hypothesis proposed by Micheal Stoker (University of Glasgow) more than 50 years ago, stating that static normal fibroblasts suppress tumor growth. Interestingly, The investigator's lineage tracing experiments showed that Meflin-positive rCAFs differentiate into Meflin-negative pCAFs during cancer progression. These studies revealed that the tumor stroma is comprised of pCAFs and rCAFs, which is analogous to the heterogeneity of tumor-infiltrating immune cells (e.g., protumor regulatory T cells versus antitumor cytotoxic T cells).

The identification of the rCAF marker Meflin enabled the investigators to develop new strategies to convert or reprogram pCAFs to rCAFs. Using a pharmacological approach, The investigators performed a chemical library screen and identified Am80, a synthetic unnatural retinoid, as a reagent that effectively converts Meflin-negative pCAFs to Meflin-positive rCAFs. Am80 administration improved the sensitivity of pancreatic cancer to chemotherapeutics. These data suggested that the conversion of pCAF to rCAFs may represent a new strategy for pancreatic cancer treatment.

The object of this study is to perform an investigator-initiated clinical study to investigate the effect of AM80 on pancreatic cancer with a combination of conventional tumoricidal agents including gemcitabine and nab-paclitaxel.

Eligibility criteria: * Inclusion Criteria:

  - Patients who meet all of the following criteria will be eligible for this study. Besides, CTCAE v5.0 will be used to determine the grade of adverse events in this study.
  1. Patients with unresectable pancreatic cancer who are histologically or cytologically diagnosed as adenocarcinoma based on the 7th edition of the Pancreatic Cancer Treatment Protocol and meet the following criteria.

     Patients who have not received any anticancer therapy (radiation therapy, chemotherapy, immunotherapy, surgery, or investigational therapy) for this disease.
  2. Patients who are between 20 and 79 years of age at the time of consent.
  3. Patients with at least one measurable lesion based on RECIST ver 1.1 in the primary pancreatic lesion confirmed by contrast-enhanced CT at the screening.
  4. Patients who are expected to survive for at least 12 weeks after the start of treatment.
  5. Patients who can understand the contents of this study and can give written consent.
  6. Patients with ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1
  7. Patients who meet the following criteria in blood tests within 7 days before enrollment and whose organ functions are preserved (if blood transfusion is used, tests must be performed at intervals of at least 2 weeks afterward)

     * Total bilirubin ≤ upper limit of institutional standard (ULN) x 1.5 (less than or equal to 3.0 mg/dL for patients undergoing ERBD or PTBD)
     * AST (GOT) and ALT (GPT) ≦ ULN × 3 (In the case of abnormal liver function due to malignancy, ≤ ULN × 5)
     * Creatinine ≤ 1.5 mg/dL or
     * Creatinine clearance ≥ 60ml/min If creatinine clearance is not measured, the estimated value should be used.
     * White blood cell count ≥ 3,500/mm3, ≤ 12,000/mm3
     * Neutrophils ≥ 1,500/mm3
     * Platelet count ≥ 100,000/mm3
     * Hemoglobin ≥ 9.0g/dL
     * Prothrombin activity level ≥ 70%
  8. Outpatients who can go to the hospital.
  9. Patients who can swallow or continue to take oral medications.
  10. For women of childbearing potential, patients who can use contraception for at least 30 days before the start of study treatment, during the study period, and for at least 2 years after the end of treatment.
  11. Patients who can undergo biopsy from pancreatic cancer ①within 28 days before the start of the study treatment and ② 8 weeks after the start of the study treatment (Day 57: acceptable range: ±7 days)
* Exclusion Criteria:

  1. Patients with any of the following complications Patients with poorly controlled heart disease (congestive heart failure, myocardial infarction, or unstable angina within 1 year before enrollment, arrhythmia requiring treatment, etc.) Poorly controlled diabetes or hypertension Active autoimmune disease requiring systemic administration of steroids or immunosuppression therapy Interstitial pneumonia or pulmonary fibrosis (patients with current grade 2 or higher)
  2. Patients who have received other clinical trial drugs or products (excluding existing chemotherapeutic agents and placebo drugs) within 4 weeks before enrolment.
  3. Patients with confirmed brain metastasis (confirmed by head CT or MRI if the patient has symptoms of brain metastasis)
  4. Patients with ascites or pleural effusion requiring drainage.
  5. Patients who fall under any of the following HBs antigen positive HCV antibody positive and HCV-RNA positive HIV antibody positive
  6. Patients with Grade 2 or higher peripheral sensory or motor neuropathy
  7. Patients with multiple cancers (multiple cancers are defined as simultaneous multiple cancers and metachronous multiple cancers with disease-free survival of 5 years or less. lesions equivalent to carcinoma in situ or intramucosal carcinoma that are considered curable by local treatment are not included in multiple cancers)
  8. Patients who have undergone surgery (excluding diagnostic biopsy and review laparoscopy) within 4 weeks before enrollment.
  9. Patients with bleeding disorders or coagulation disorders that preclude the safe biopsy under EUS (e.g., significant intratumoral bleeding, coagulation disorders, history of bleeding disorders, or complications).
  10. Patients with a history of allergy to the trial drug, combination chemotherapy, its additives, or vitamin A products.
  11. Patients requiring anticoagulant medication.
  12. Patients with cerebral infarction, pulmonary infarction, other arterial or venous thrombosis or its sequelae with clinical symptoms.
  13. Patients with gastrointestinal disorders that may affect the absorption of the investigational drug.
  14. Female patients who are pregnant or breastfeeding (unless breastfeeding is discontinued and not resumed).
  15. Male patients whose sex partner is a woman who wishes to become pregnant.
  16. Patients with vitamin A overload.
  17. Patients receiving vitamin A preparations or regularly using vitamin A-containing supplements (patients can be enrolled if the administration is discontinued at the time of obtaining consent).
  18. Other patients deemed inappropriate by the investigator or sub-investigator.

Primary outcomes:
measure: Phase I study; DLT (dose-limiting toxicity)
timeFrame: The DLT evaluation period is from Day 1, the start date of study drug administration, to Day 28 of Phase I study.
measure: Phase II study; response rate (based on RECIST ver1.1)
timeFrame: through phase II study completion,an average of half year.
Secondary outcomes:
measure: AE（Adverse events）
timeFrame: All of the clinical trial period (up to 6 cycles, 28 days per cycle)
measure: OS（Overall survival）
timeFrame: The time from the date of first dose of MIKE-1 until date of death from any cause. The cut-off date is the end of post-observation for all patients.
measure: PFS（Progression-free survival）
timeFrame: The time from date of first dose of MIKE-1 to date of first documentation of disease progression or death, whichever occurs. The cut-off date is the end of post-observation for all patients.
measure: Area under the blood concentration time curve (AUC)
timeFrame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
measure: Peak Plasma Concentration (Cmax)
timeFrame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
measure: Elimination half-life (t1/2)
timeFrame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
measure: Clearance (CL)
timeFrame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
measure: Mean residence time (MRT)
timeFrame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
measure: Volume of distribution (Vds)
timeFrame: 1, 2, 4, 8, 10, and 24 hours after first dosing in phase I.
measure: Response rate （Phase I）
timeFrame: All of the clinical trial period (up to 6 cycles, 28 days per cycle)
Other outcomes:
Locations:
city: Nagoya
country: Japan
facility: Nagoya University Hospital
state: Aich
city: Tokyo
country: Japan
facility: The University of Tokyo Hospital
Study officials:
affiliation: Nagoya University
name: Hiroki Kawashima
role: PRINCIPAL_INVESTIGATOR
affiliation: The University of Tokyo Hospital
name: Mitsuhiro Fujishiro
role: STUDY_CHAIR
References:
citation: Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, Esaki N, Ushida K, Mii S, Shiraki Y, Ando K, Weng L, Ishihara S, Ponik SM, Conklin MW, Haga H, Nagasaka A, Miyata T, Matsuyama M, Kobayashi T, Fujii T, Yamada S, Yamaguchi J, Wang T, Woods SL, Worthley D, Shimamura T, Fujishiro M, Hirooka Y, Enomoto A, Takahashi M. Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis. Cancer Res. 2019 Oct 15;79(20):5367-5381. doi: 10.1158/0008-5472.CAN-19-0454. Epub 2019 Aug 22.
citation: Kobayashi H, Gieniec KA, Wright JA, Wang T, Asai N, Mizutani Y, Lida T, Ando R, Suzuki N, Lannagan TRM, Ng JQ, Hara A, Shiraki Y, Mii S, Ichinose M, Vrbanac L, Lawrence MJ, Sammour T, Uehara K, Davies G, Lisowski L, Alexander IE, Hayakawa Y, Butler LM, Zannettino ACW, Din MO, Hasty J, Burt AD, Leedham SJ, Rustgi AK, Mukherjee S, Wang TC, Enomoto A, Takahashi M, Worthley DL, Woods SL. The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis. Gastroenterology. 2021 Mar;160(4):1224-1239.e30. doi: 10.1053/j.gastro.2020.11.011. Epub 2020 Nov 14.
citation: Stoker MG, Shearer M, O'Neill C. Growth inhibition of polyoma-transformed cells by contact with static normal fibroblasts. J Cell Sci. 1966 Sep;1(3):297-310. doi: 10.1242/jcs.1.3.297. No abstract available.
citation: Iida T, Mizutani Y, Esaki N, Ponik SM, Burkel BM, Weng L, Kuwata K, Masamune A, Ishihara S, Haga H, Kataoka K, Mii S, Shiraki Y, Ishikawa T, Ohno E, Kawashima H, Hirooka Y, Fujishiro M, Takahashi M, Enomoto A. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics. Oncogene. 2022 May;41(19):2764-2777. doi: 10.1038/s41388-022-02288-9. Epub 2022 Apr 13.
citation: Mizutani Y, Iida T, Ohno E, Ishikawa T, Kinoshita F, Kuwatsuka Y, Imai M, Shimizu S, Tsuruta T, Enomoto A, Kawashima H, Fujishiro M. Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma. BMC Cancer. 2022 Feb 24;22(1):205. doi: 10.1186/s12885-022-09272-2.